BioSpace News Archive

Proteins are the most important and largest biomolecules and extremely vital to the functioning of an organism.

Researchers have been identifying the different areas in airways and lungs to develop drugs for offering a better quality of life to patients suffering from asthma and chronic obstructive pulmonary disease (COPD).

Motus GI Holdings, Inc. reported its financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

CohBar, Inc., a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financial and operating results and provided a business update.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Tricida, Inc. announced financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2021 and provided a corporate update.